Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:39 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation
NCT03066115 · University of Wisconsin, Madison · PHASE1 · withdrawn · last registry update 2019-01-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This study was never funded, never fully IRB approved, and thus never enrolled anyone.” | – | Registry record, University of Wisconsin, Madison |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against NOS1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-12-17Also stopped (terminated): National Heart, Lung, and Blood Institute (NHLBI), L-NMMA + Acetylcholine (NCT00327080)
- 2019-08-15Also stopped (withdrawn): Medical University of Vienna, NG-monomethyl-L-arginine (L-NMMA) + Endothelin-1 (ET-1) (NCT00406731)
- 2018-08-15Also stopped (terminated): Emory University, Tetraethylammonium (TEA) + L-NG-monomethyl Arginine (L-NMMA) (NCT00166166)
- 2018-05-29Results posted on the registry: Vanderbilt University, Sitagliptin + Pegvisomant (NCT01701973)
- 2018-05-23Phase 3 first posted: University Health Network, Toronto, Teduglutide + Normal Saline + Teduglutide + L-NMMA (NCT03534661)
- 2018-01-23Results posted on the registry: University of Michigan, Procedure: Regional phenylephrine arterial infusion (NCT00356265)
- 2018-01-23Also stopped (terminated): University of Michigan, Procedure: Regional phenylephrine arterial infusion (NCT00356265)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision